Total trials
84
Active
11
Phase 3
33
Total enrollment
25,873
Pipeline matrix
Showing 22 of 22 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Metformin | — | — | — | — | 3 | ||
| Alogliptin | — | — | — | — | 2 | ||
| CT-P55 | — | — | — | — | 2 | ||
| EU-approved Cosentyx | — | — | — | — | 2 | ||
| Empagliflozin | — | — | — | — | — | 2 | |
| CT-P51 | — | — | — | — | — | 1 | |
| EU-approved Keytruda | — | — | — | — | — | 1 | |
| CT-P44 | — | — | — | — | — | 1 | |
| Darzalex Faspro | — | — | — | — | — | 1 | |
| CT-P53 | — | — | — | — | — | 1 | |
| US-Ocrevus | — | — | — | — | — | 1 | |
| EU-Ocrevus | — | — | — | — | — | 1 | |
| L03RD1 | — | — | — | — | — | 2 | |
| L03RD2 | — | — | — | — | — | 2 | |
| L03TD1 | — | — | — | — | — | 1 | |
| CT-P52 | — | — | — | — | — | 1 | |
| Ixekizumab | — | — | — | — | — | 1 | |
| Ustekinumab 45 mg | — | — | — | — | — | 1 | |
| Ustekinumab 90 mg | — | — | — | — | — | 1 | |
| Omalizumab | — | — | — | — | — | 1 | |
| Remsima IV | — | — | — | — | — | 1 | |
| Remsima SC | — | — | — | — | — | 1 |
Next readouts
- 2026-02-18
- 2026-03-31
- 2026-05-24
- 2026-08
- 2026-12
- 2027-02
- 2027-02
- 2027-03
- 2027-09-30
- 2027-11-15
Top conditions
- Rheumatoid Arthritis14
- Healthy12
- Essential Hypertension4
- SARS-CoV-2 Infection4
- Crohn's Disease4
- Ankylosing Spondylitis4
- Healthy Male Subjects4
- Ulcerative Colitis3
Frequently asked questions about Celltrion
- How many clinical trials does Celltrion have on ClinicalTrials.gov?
- Celltrion is listed as the lead sponsor on 84 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Celltrion's trials are in Phase 3?
- 33 of Celltrion's trials are in Phase 3, spread across 22 active drug programs.
- What therapeutic areas does Celltrion focus on?
- Celltrion's most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Healthy, Essential Hypertension, SARS-CoV-2 Infection, Crohn's Disease.
- When are Celltrion's next clinical trial readouts?
- Celltrion has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis”, expected around 2026-02-18.